Liquidia (LQDA) Change in Accured Expenses (2020 - 2026)
Liquidia's (LQDA) quarterly Change in Accured Expenses came in at $14.5 million in Q1 2026, up 401.62% year-on-year from $2.9 million in Q1 2025, and down 55.63% quarter-over-quarter from $32.8 million in Q4 2025.
Liquidia (LQDA) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Liquidia's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $14.5 million for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 401.62% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $73.9 million, a 32649.78% increase from a year earlier, with the FY2025 full-year figure at $54.5 million, up 937.04% from the prior year.
- Change in Accured Expenses fell to $14.5 million in Q1 2026 per LQDA's latest filing, from $32.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $32.8 million in Q4 2025 and bottomed at -$4.8 million in Q1 2025.
- The 5-year median for Change in Accured Expenses is $1.8 million (2023), against an average of $4.9 million.
- Biggest YoY gain for Change in Accured Expenses was 1913.33% in 2023; the steepest drop was 3781.43% in 2023.
- Year by year, Change in Accured Expenses stood at $330000.0 in 2022, then surged by 1913.33% to $6.6 million in 2023, then sank by 70.38% to $2.0 million in 2024, then soared by 1564.28% to $32.8 million in 2025, then sank by 55.63% to $14.5 million in 2026.
- Per Business Quant, the three latest LQDA Change in Accured Expenses figures stand at $14.5 million (Q1 2026), $32.8 million (Q4 2025), and $17.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 14.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.53 Mn |
| Mar 31, 2026 | 14.53 Mn |
| Dec 31, 2025 | 32.75 Mn |
| Dec 31, 2025 | 32.75 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Jun 30, 2025 | 8.68 Mn |
| Jun 30, 2025 | 8.68 Mn |
| Mar 31, 2025 | -4.82 Mn |
| Mar 31, 2025 | -4.82 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | -968,000.00 |
| Jun 30, 2024 | -968,000.00 |
| Mar 31, 2024 | 668,000.00 |
| Mar 31, 2024 | 668,000.00 |
| Dec 31, 2023 | 6.64 Mn |
| Dec 31, 2023 | 6.64 Mn |